STAT+: Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate

STAT PlusBiotech Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate Tango plans to move the combo approach to a Phase 3 trial Manage alerts for this article Email this article Share this article By Andrew JosephJune 8, 2026 Europe Correspondent Andrew Joseph[email protected]Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Revolution Medicines’ experimental pancreatic cancer drug has been the star of the oncology field in recent weeks, with new data showing the medicine produced unprecedented outcomes for patients. Its next act — this time as a co-lead — was revealed Monday.Advertisement Tango Therapeutics said that in an early-stage clinical trial, a combination of its drug vopimetostat along with Revolution’s daraxonrasib led to a durable responses in the large majority of pancreatic cancer patients who received both medicines. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, Cancer, drug development, Pharmaceuticals, STAT+ Submit a correction requestReprints Andrew Joseph Europe Correspondent Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended The Readout June 8, 2026 STAT Plus: Novo underwhelmed by drug it once fought Pfizer for Biotech June 8, 2026 STAT Plus: J&J spends $1 billion to enter KRAS race for cancer treatments Advertisement Opinions+ June 8, 2026 $2 million gene therapy cures require a financing model Pharma June 6, 2026 STAT Plus: Lilly shares safety, tolerability data on its next-gen obesity drug Pharma June 6, 2026 STAT Plus: Detailed data show Pfizer’s monthly obesity drug continues to show potential Subscriber Picks